CA1148859A - Simultaneous assay of two hepatitis viruses using a solid phase - Google Patents
Simultaneous assay of two hepatitis viruses using a solid phaseInfo
- Publication number
- CA1148859A CA1148859A CA000346729A CA346729A CA1148859A CA 1148859 A CA1148859 A CA 1148859A CA 000346729 A CA000346729 A CA 000346729A CA 346729 A CA346729 A CA 346729A CA 1148859 A CA1148859 A CA 1148859A
- Authority
- CA
- Canada
- Prior art keywords
- hepatitis
- sample
- solid phase
- labeled
- markers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 24
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 24
- 239000007790 solid phase Substances 0.000 title claims abstract description 17
- 241000700605 Viruses Species 0.000 title claims abstract description 10
- 238000003556 assay Methods 0.000 title description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 208000002672 hepatitis B Diseases 0.000 claims description 17
- 101710132601 Capsid protein Proteins 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 14
- 239000003550 marker Substances 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000011324 bead Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 229940072417 peroxidase Drugs 0.000 description 4
- 102000013415 peroxidase activity proteins Human genes 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 208000005252 hepatitis A Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000543381 Cliftonia monophylla Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 101710142246 External core antigen Proteins 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001354491 Lasthenia californica Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 108091005979 iodinated proteins Proteins 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Sampling And Sample Adjustment (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4831979A | 1979-06-14 | 1979-06-14 | |
| US48,319 | 1979-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1148859A true CA1148859A (en) | 1983-06-28 |
Family
ID=21953924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000346729A Expired CA1148859A (en) | 1979-06-14 | 1980-02-29 | Simultaneous assay of two hepatitis viruses using a solid phase |
Country Status (12)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0058428B1 (en) * | 1981-02-18 | 1985-10-09 | Eisai Co., Ltd. | An enzyme immuno-assay for simultaneously measuring a plurality of samples and test vessel for carrying out this method |
| GB2165046B (en) * | 1982-02-10 | 1986-10-15 | Baker Terence S | Ligand molecule |
| IE54109B1 (en) * | 1982-02-10 | 1989-06-21 | Boots Celltech Diagnostics | Assay |
| JPS58187861A (ja) * | 1982-04-26 | 1983-11-02 | Otsuka Pharmaceut Co Ltd | 成人型ｔ細胞性白血病関連抗体の測定法 |
| GB2125547B (en) * | 1982-07-31 | 1986-04-23 | Mochida Pharm Co Ltd | Simultaneous immunoassay of two or more substances |
| JPS5984162A (ja) * | 1982-11-05 | 1984-05-15 | Toshiba Corp | 免疫分析法 |
| EP0131974A1 (en) * | 1983-06-08 | 1985-01-23 | Akzo N.V. | Determination of delta-antigens in body fluids |
| EP0139316B1 (en) * | 1983-09-14 | 1989-04-05 | Akzo N.V. | Method for the immunochemical determination of hepatitis b core antigens |
| US4701421A (en) * | 1984-08-27 | 1987-10-20 | Akzo, N.V. | Determination of protecting anti-HBV immunoglobulins |
| GB8607101D0 (en) * | 1986-03-21 | 1986-04-30 | Serono Diagnostics Ltd | Immunoassay |
| AU1334588A (en) * | 1987-03-23 | 1988-09-22 | Ortho Pharmaceutical Corporation | Assay for detecting hepatitis antigens and aids antibodies |
| CA1335880C (en) * | 1988-07-14 | 1995-06-13 | Thomas P. O'connor | Detection of an antibody and antigen in an immunoassay |
| EP0438457A1 (en) * | 1988-10-14 | 1991-07-31 | Syntello Ab | A method for simultaneous detection of different types of antibodies and/or antigens produced by individual cells |
| DE3919810A1 (de) * | 1989-06-16 | 1990-12-20 | Biochrom Beteiligungs Gmbh & C | Festphasenimmunoassay und testbesteck zur bestimmung von antigenen und antikoerpern |
| AT394114B (de) * | 1989-07-13 | 1992-02-10 | Immuno Ag | Verfahren zur bestimmung von antigenen und/oder antikoerpern in menschlichen koerperfluessigkeiten sowie set zur durchfuehrung des verfahrens |
| EP0473065A3 (en) * | 1990-08-29 | 1992-08-26 | Abbott Laboratories | Simultaneous assay for detecting two or more analytes |
| DE4236189A1 (de) * | 1992-10-27 | 1994-04-28 | Boehringer Mannheim Gmbh | Verfahren zur simultanen Bestimmung von Antigenen und Antikörpern |
| EP1020727B1 (en) * | 1998-07-30 | 2008-10-29 | Advanced Life Science Institute, Inc. | Method for assaying hepatitis c virus |
| EP1672366A3 (en) * | 1999-06-11 | 2007-11-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for opsonophagocytic assays |
| JP4353793B2 (ja) * | 2001-06-26 | 2009-10-28 | アボット・ラボラトリーズ | Ｈｃｖ抗原とｈｃｖ抗体との同時検出のための方法 |
| US7101683B2 (en) | 2001-06-26 | 2006-09-05 | Abbott Laboratories | Methods for the simultaneous detection of HCV antigens and HCV antibodies |
| US7332269B2 (en) | 2001-11-11 | 2008-02-19 | Ortho-Clinical Diagnostics, Inc. | HCV core protein sequences |
| WO2014176535A1 (en) | 2013-04-26 | 2014-10-30 | Bio-Rad Laboratories, Inc. | Multiplex hepatitis b assay |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3867517A (en) * | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| GB1506017A (en) * | 1974-03-04 | 1978-04-05 | Int Diagnostic Tech | Fluorometric system and method for the detection of biologically derived substances |
| SE7610683L (sv) * | 1975-09-29 | 1977-06-10 | Cordis Corp | Metod for bestemning av nervaron av ett antigen associerat med hepatit |
| AT343822B (de) * | 1976-08-20 | 1978-06-26 | Immuno Ag | Radioimmunologisches verfahren und einrichtung zur bestimmung von antigenen |
| DE2803154C2 (de) * | 1977-01-27 | 1986-07-24 | Becton, Dickinson and Co., Paramus, N.J. | Gleichzeitige Radiountersuchung von Folat und Vitamin B 12 |
| CA1100037A (en) * | 1977-03-11 | 1981-04-28 | Chung-Mei Ling | Hb.sub.c ag coated on solid phase |
| US4102996A (en) * | 1977-04-20 | 1978-07-25 | Merck & Co., Inc. | Method of preparing hepatitis B core antigen |
| US4189464A (en) * | 1978-05-05 | 1980-02-19 | Institute For Cancer Research | Hepatitis B testing reagent and method |
| IL55816A (en) * | 1978-10-30 | 1982-04-30 | Ames Yissum Ltd | Method for simultaneous immunoassay of several different antibodies and a kit therefor |
-
1980
- 1980-02-29 CA CA000346729A patent/CA1148859A/en not_active Expired
- 1980-03-06 ZA ZA00801318A patent/ZA801318B/xx unknown
- 1980-03-06 AU AU56226/80A patent/AU530580B2/en not_active Ceased
- 1980-03-11 GB GB8008095A patent/GB2051357B/en not_active Expired
- 1980-03-20 NL NL8001661A patent/NL8001661A/nl not_active Application Discontinuation
- 1980-05-07 IT IT21874/80A patent/IT1140846B/it active
- 1980-06-06 JP JP7568180A patent/JPS562558A/ja active Granted
- 1980-06-11 DE DE3021891A patent/DE3021891C2/de not_active Expired
- 1980-06-12 AT AT0309980A patent/AT368813B/de not_active IP Right Cessation
- 1980-06-13 FR FR8013217A patent/FR2459482A1/fr active Granted
- 1980-06-13 CH CH4579/80A patent/CH654113A5/fr not_active IP Right Cessation
- 1980-06-13 BE BE0/201040A patent/BE883824A/fr not_active IP Right Cessation
-
1990
- 1990-01-16 JP JP2004676A patent/JPH02276969A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU530580B2 (en) | 1983-07-21 |
| ATA309980A (de) | 1982-03-15 |
| JPH0220945B2 (enrdf_load_stackoverflow) | 1990-05-11 |
| FR2459482A1 (fr) | 1981-01-09 |
| CH654113A5 (fr) | 1986-01-31 |
| DE3021891C2 (de) | 1983-08-04 |
| IT8021874A0 (it) | 1980-05-07 |
| IT1140846B (it) | 1986-10-10 |
| AU5622680A (en) | 1980-12-18 |
| NL8001661A (nl) | 1980-12-16 |
| AT368813B (de) | 1982-11-10 |
| BE883824A (fr) | 1980-12-15 |
| GB2051357B (en) | 1983-05-18 |
| ZA801318B (en) | 1981-02-25 |
| GB2051357A (en) | 1981-01-14 |
| JPH02276969A (ja) | 1990-11-13 |
| JPS562558A (en) | 1981-01-12 |
| DE3021891A1 (de) | 1980-12-18 |
| FR2459482B1 (enrdf_load_stackoverflow) | 1984-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1148859A (en) | Simultaneous assay of two hepatitis viruses using a solid phase | |
| US4062935A (en) | Immunoassay involving the binding of RF to the antigen-antibody complex | |
| EP1047943B1 (en) | Chromatographic assay device and method for detecting the presence of an analyte in a blood sample | |
| DK165381B (da) | Immunoanalysemetode til bestemmelse af ligander ved hjaelp af biotin og antibiotin | |
| JP2636331B2 (ja) | 抗原特異的な抗体の一段階測定法およびそれに適する試薬 | |
| JPH0346561A (ja) | 分析物検出のための方法、試薬及び試験ストリップ | |
| JPS6171360A (ja) | 血清中の抗原及び抗体の同時検定のためのアツセイ | |
| CA2008304C (en) | Assay for bone alkaline phosphatase | |
| CA1261740A (en) | Immunoassay for detection of common determinant antibody to hepatitis b | |
| JPS63128260A (ja) | 抗ｈｉｖの測定法、そのための手段およびその使用 | |
| Rizzetto et al. | A radioimmunoassay for HBcAg in the sera of HBsAg carriers: Serum HBcAg, serum DNA polymerase activity, and liver HBcAg immunofluorescence as markers of chronic liver disease | |
| CA2008100A1 (en) | Method for the determination of immunologically detectable substance | |
| RU2065164C1 (ru) | Диагностическая тест-система для выявления вируса гепатита а | |
| CA1106281A (en) | Detection of antigen associated with hepatitis by "sandwich" method | |
| JP2001221802A (ja) | 抗ＨＢｃ抗体の免疫測定法 | |
| EP0154392A2 (en) | Processes for the detection of non-A, non-B hepatitis and a kit for use in the same | |
| EP0131974A1 (en) | Determination of delta-antigens in body fluids | |
| EP0139316B1 (en) | Method for the immunochemical determination of hepatitis b core antigens | |
| Ling et al. | Simultaneous detection of indicators of hepatitis virus exposure | |
| CA1123733A (en) | Hepatitis be-antigen and antibodies in insoluble form | |
| AU645970B2 (en) | A method for the determination of antibodies against organisms causing infectious diseases in body fluids, agents for this purpose and the use thereof in this method | |
| FI95417B (fi) | Menetelmä ja reagenssi vasta-aineiden määrittämiseksi | |
| JPH08506663A (ja) | ワン−ポットアッセイ | |
| CA1086647A (en) | Sugar coated reagents for solid phase immunoassay | |
| CA1233116A (en) | Determination of protecting anti-hbv immunoglobulins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |